Cabaletta Bio Welcomes Sarah Yuan, PhD, as New Chief Technology Officer
August 21, 2024
| BioBuzz’s mission is simple: to be more connected. Our regionally-focused storytelling, programs, events and experiences connect, amplify and create impact across the life science workforce in growing biohubs. Submit your People On The Move (free and ongoing) to showcase your company’s growth by promoting your new hires and recent promotions. |
Cabaletta Bio is excited to announce the appointment of Dr. Sarah Yuan as the new Chief Technology Officer. Dr. Yuan’s addition to the team is a significant milestone for the company, reflecting its commitment to advancing cell therapy innovations.
CEO & Co-founder, Steven Nichtberger, stated “Sarah brings substantial cell therapy development and
commercial launch experience, including at bluebird bio and 2seventy bio, where she was instrumental in the regulatory approval process for Abecma™ and two other cell therapy medicines.”
About Dr. Sarah Yuan
Dr. Yuan comes to Cabaletta Bio with over two decades of expertise in cell therapy manufacturing and supply chain management. Her impressive career includes key contributions to the development, launch, and commercialization of Abecma™. She has previously played critical roles at bluebird bio and 2seventy bio, where her involvement in regulatory approvals was instrumental in the success of Abecma™ and two other cell therapy medicines.
Prior to her new role at Cabaletta Bio, Dr. Yuan served as Chief Technical Operations Officer at Sigilon Therapeutics, leading the CMC efforts for their novel Shielded Living Therapeutics™ platform. Her extensive background also includes serving as Vice President of Process and Analytical Development at 2seventy bio, and holding various leadership positions in External Manufacturing, Technical Development, and CMC Strategies at Sanofi, Bioverativ, Biogen, Agenus, and Millipore. Dr. Yuan earned her Ph.D. in Chemical Engineering from the University of Wisconsin-Madison and her B.S. from the University of California, Berkeley.
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical trials in systemic lupus erythematosus, myositis, systemic sclerosis and generalized myasthenia gravis and in the RESET-PV™ sub-study within the DesCAARTes™ clinical trial in pemphigus vulgaris, along with the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK-associated myasthenia gravis. The expanding CABA™ platform is designed to develop potentially curative therapies that offer deep and durable responses for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA.
- About the Author
- Latest Posts
BioBuzz is a community led, experience focused, biotech and life sciences media and events company. BioBuzz highlights regional breaking news, industry professionals, jobs, events, and resources for business and career growth. Their weekly newsletter is subscribed to by thousands in the BioHealth Capital Region and Greater Philadelphia as the go-to for industry updates.
